Childrens Health System of Texas
Childrens hospital
Based in TX
🤖
AI Overview
With $2.0M in lobbying spend across 22 quarterly filings, Childrens Health System of Texas is a significant lobbying presence. They deploy 16 individual lobbyists
$2.0M
Total Lobbying Spend
22
Quarterly Filings
1
Lobbying Firms Used
16
Individual Lobbyists
Spending by Year
| Year | Lobbying Spend |
|---|---|
| 2018 | $80K |
| 2019 | $180K |
| 2020 | $90K |
| 2021 | $360K |
| 2022 | $270K |
| 2023 | $360K |
| 2024 | $360K |
| 2025 | $270K |
Lobbying Firms
ARNOLD & PORTER KAYE SCHOLER LLP
What They Lobby For
- Issues related to Section 1115 Medicaid Delivery System Reform Incentive Payment (DSRIP) Waiver, Medicaid Disproportionate Share Hospital (DSH) Payments, and other pediatric health issues including H.R. 3325 ACE Kids Act regarding Health Home services for medically complex children.
- Issues related to Children's Hospitals Graduate Medical Education (CHGME) annual funding, as well as other pediatric health funding issues.
- Issues related to Medicaid, coordinated care model for children's health, telehealth, Children's Health Insurance Program (CHIP), Disproportionate Share Hospital (DSH) payments, medical education, and other pediatric health issues.
- Issues related to Medicaid Disproportionate Share Hospital (DSH) Payments, and other pediatric health issues including H.R.1839 - Medicaid Services Investment and Accountability Act of 2019 in regards to Health Home services for medically complex children.
- Issues related to Medicaid, coordinate care model for children's health, telehealth, Children's Health Insurance Program (CHIP), Disproportionate Share Hospital (DSH) payments, surprise medical billing, medical education, and other pediatric health issues.
- Issues related to Medicaid Disproportionate Share Hospital (DSH) Payments, and other pediatric health issues. Prescription Drug Pricing Reduction Act (S. 2543). Elijah E. Cummings Lower Drug Costs Now Act (H.R. 3).
- Issues related to Medicaid, coordinated care model for children's health, telehealth, Children's Health Insurance Program (CHIP), Disproportionate Share Hospital (DSH) Payments, surprise medical billing, medical education, high cost specialty drugs, and other pediatric health issues. Prescription Drug Pricing Reduction Act (S. 2543). Elijah E. Cummings Lower Drug Costs Now Act (H.R. 3).
- Issues related to Medicaid, coordinated care model for children's health, telehealth, Children's Health Insurance Program (CHIP), Disproportionate Share Hospital (DSH) Payments, surprise medical billing, medical education, high cost specialty drugs, and other pediatric health issues. Policy issues related to hospital funding and the federal response to the COVID-19 virus, including the CARES Act (H.R. 748). Prescription Drug Pricing Reduction Act (S. 2543). Elijah E. Cummings Lower Drug Costs Now Act (H.R. 3).
- Issues related to Medicaid Disproportionate Share Hospital (DSH) Payments, and other pediatric health issues. Policy issues related to hospital funding and the federal response to the COVID-19 virus, the CARES Act (H.R. 748). Prescription Drug Pricing Reduction Act (S. 2543). Elijah E. Cummings Lower Drug Costs Now Act (H.R. 3).
- Issues related to Medicaid, coordinated care model for children's health, telehealth, Children's Health Insurance Program (CHIP), medical education, high cost specialty drugs, and other pediatric health issues, and policy issues related to hospital funding and the federal response to the COVID-19 virus, including in the American Rescue Plan Act (H.R. 1319). Issues related to the Provider Relief Fund established by the CARES Act (Pub.L. 116-136).
Related Investigations
Big Pharma's $452M Lobbying Machine
How pharmaceutical companies spend hundreds of millions to influence health policy.
Federal Lobbying Statistics 2025
The definitive stats — $15.2B total, industry breakdowns, and trends.
What Is Lobbying? A Complete Guide
How lobbying works, who does it, and why it matters.
Explore More
Data Sources: Senate LDA Filings
Last updated: February 2026
This site is an independent journalism project. Analysis and editorial content are not affiliated with or endorsed by any government agency.